Markets

ArQule Inc. (ARQL) in Focus: Stock Rises 8.21% - Tale of the Tape

ArQule Inc. ( ARQL ) was a big mover last session as the company saw its shares rise over 8% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $1.34 to $1.62 in the past one-month time frame, showed a pick-up yesterday at $1.45.

The company has seen 1 downward estimate revision in the past month, while its Zacks Consensus Estimate of a loss widened over the same timeframe, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

ArQule Inc. (ARQL) currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Other attractive players in the healthcare industry include Myriad Genetics Inc. ( MYGN ) and ANI Pharmaceuticals, Inc. ( ANIP ), carrying a Zacks Rank #1 (Strong Buy) and Ariad Pharmaceuticals Inc. ( ARIA ) with a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

ARQULE INC (ARQL): Free Stock Analysis Report

MYRIAD GENETICS (MYGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MYGN ANIP

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More